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Kynurenines in cognitive functions: their possible role  
in depression
Depression can originate from changes in tryptophan availability, caused by activation 
of the kynurenine pathway (KP) as a result of inflammation. Alterations in the KP and the 
changing levels of its metabolites have recently been considered to be factors contributing 
to the pathogenesis of depression. The key molecular mediator which induces the conver-
sion of tryptophan into kynurenine is indoleamine-2,3-dioxygenase. Following its activation, 
both the production of neurotoxic compounds and the diminished peripheral accessibility 
of tryptophan are regarded as essential steps in the pathophysiological processes. The aim 
of this review is to survey the role of the KP in depression and its relationships with cognitive 
functions.
(Neuropsychopharmacol Hung 2012; 14(4): 239-244; doi: 10.5706/nph201212004)
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Stress, originally an engineering term, was intro-duced into the language of human physiology by 
Hans Selye in 1936. Selye put forward the view that 
stress is a condition which seriously perturbs the physi-
ological and psychological homeostasis of an organism, 
and that chronic stress can lead to the development 
of mental disorders. He suggested that the hypotha-
lamic-pituitary-adrenal (HPA) axis plays a central role 
in regulating the stress response. The disadvantages 
of chronic stress were at first thought to be due to 
hypersecretion of the glucocorticoids (cortisol and 
corticosterone), elevated levels of which can damage 
the hippocampal neurons, and particularly the pyrami-
dal neurons in the CA3 region (Nestler et al., 2002).
Depression is a severe psychiatric disorder which 
affects up to 20% of the adult population through-
out the world, accompanied by enormous mental 
suffering and one of the major causes of disability 
worldwide. One of the factors involved in the patho-
physiology of depression is a dysfunction of the 
monoaminergic system, a system that exuberantly 
projects to the prefrontal cortical, limbic and stri-
atal structures presumed to be responsible for the 
behavioural and visceral aspects of mood disorders 
(Nestler et al., 2002). 
Obviously, the endocrine and immune systems 
also participate prominently in the pathology of these 
diseases (Brambilla et al., 2000). The fundamental 
hormonal response to stress is activation of the HPA 
axis, including secretion of the corticotropin releas-
ing hormone (CRH) and arginine-vasopressin from 
the hypothalamus, followed by release of the adren-
ocorticotropic hormone from the pituitary, which 
stimulates the secretion of glucocorticoids from the 
adrenal cortex. It is known that chronic stress can 
lead to depression or depressive-like behaviour, and 
abnormalities of the HPA axis have been found in 
patients with major depression. Women with depres-
sion exhibit a higher degree of HPA axis activation 
than depressed men, and the extent of dysregulation 
of the HPA axis is greatest during the menopause, 
when women are exposed to the loss of oestrogens. 
A decline of the testosterone level in males can also 
cause depression. Concerning the HPA axis, both 
an increased level of CRH and the enhanced secre-
tion and reactivity of cortisol can induce depression 
(Weizman et al., 2012).  
There is a growing body of evidence which suggests 
that changes in the glutamatergic system and mainly 
in the function of N-methyl-D-aspartate (NMDA) re-
ceptors play a role in hippocampal synaptic plasticity 
deficiencies, and thereby in the loss or atrophy of cells, 
which results in the morphometric changes that can 
be observed in patients with severe, chronic mood 
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disorders (Maeng & Zarate, 2007). Imaging studies 
involving patients with major depressive disorders 
have revealed decreases of approximately 10% in the 
right hippocampal volume and of about 10-20% in 
the left hippocampal volume. This demonstrated the 
existence of a correlation between the total lifetime 
duration of depression and hippocampal shrinkage 
(Szakács et al., 2012). Inflammatory processes acti-
vate the kynurenine pathway (KP) which reduces the 
availability of tryptophan (TRP), thereby potentially 
contributing to the pathogenesis of depression. 
TrypTophan meTabolism
TRP is an essential amino acid, required for the bio-
synthesis of proteins, 5-hydroxytryptamine (5-HT, 
serotonin) and niacin. There are two major metabolic 
routes for TRP degradation in the brain: the methoxy-
indole pathway and the KP (Oxenkrug et al., 2010). 
A large variety of external and internal processes can 
induce the oxidative catabolism of TRP.
The meThoxyindole paThway
The accessibility of TRP as a substrate is the first 
rate-limiting factor during the pathway because 
less than 5% of TRP is degraded through this route. 
The hydroxylation of TRP catalysed by tryptophan- 
hydroxylase, which results in 5-hydroxytryptophan, 
is a rate-determining step. The next step is decar-
boxylation, which leads to the formation of 5-HT. 
5-HT functions as a neurotransmitter in the brain; 
after it is released from the synaptic nerve terminals, 
it binds to its receptors (5-HT1-7) in the synaptic cleft. 
5-HT is also a substrate of melatonin synthesis; its 
N-acetylation, followed by O-methylation, furnishes 
5-methoxy-N-acetyltryptamine (melatonin). A lack 
or deficient production of 5-HT, N-acetyl-5-HT or 
melatonin contributes to mood disturbances and de-
pression (Lewy et al., 1980), sleeping problems and 
disturbances in the circadian rhythm (Oxenkrug & 
Requintina, 2003). 
The Kynurenine paThway
The other major route of TRP metabolism is the 
KP, in which the central compound is kynurenine 
(KYN). KYN is generated from TRP by the action of 
indoleamine-2,3-dioxygenase (IDO) or tryptophan-
2,3-dioxygenase (TDO). IDO is present in the pe-
riphery and also in the brain, while TDO is largely 
located in the liver. About 95% of the TRP is broken 
down via this pathway. KYN can be metabolized in 
two distinct pathways, serving as a precursor of the 
neuroprotective kynurenic acid (KYNA) or the neu-
rotoxic 3-hydroxy-L-kynurenine (3-OH-KYN) and 
quinolinic acid (QUIN). 40% of the KYN content of 
the mammalian brain is produced locally in the brain, 
and 60% is taken up from the blood by a large neu-
tral amino acid carrier. KYN is converted to KYNA 
through irreversible transamination by kynurenine 
aminotransferases (KATs), the biosynthetic enzymes 
of KYNA formation in the brain (Guidetti et al., 2007).
KYNA is one of the main TRP metabolites pro-
duced by the neurons and astrocytes via the KP in 
the mammalian brain (Robotka et al., 2008). It has 
been shown that KYNA in nanomolar concentrations 
exerts a neuromodulatory effect, whereas in supra-
physiological concentrations it has proved to be a 
broad-spectrum endogenous antagonist of ionotropic 
excitatory amino acid receptors, and inhibits the neu-
ronal activity (Rozsa et al., 2008). In low micromolar 
concentrations, it blocks the NMDA receptor activ-
ity, displays high affinity for the glycine-binding site 
of the NMDA receptor, and is additionally a weak 
antagonist of the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid and kainate receptors (Sas 
et al., 2007). Consequently, an elevation in KYNA 
concentration under physiological conditions can 
result in a cognitive impairment (Potter et al., 2010). 
In contrast, under pathological conditions, the situ-
ation can be quite different. Overactivation of the 
NMDA receptors occurs following glutamate excito-
toxicity and anti-glutamatergic drugs can help in the 
restoration of the basal level of activation, facilitating 
a memory recovery in a cognitive impairment.
The α7-nicotinic acetylcholine (α7-nACh) recep-
tors are non-competitively inhibited by KYNA and 
it can increase the expression of non-α7-nACh re-
ceptors (Pereira et al., 2002). It has been established 
that cross-talk exists between the cholinergic system 
and KYNA, a situation which has been surmised 
to play a role in the pathogenesis of several brain 
lesions (Alkondon et al., 2004). With regard to its 
pharmacological activity, KYNA appears to have 
a neuroprotective potential, but in very high concen-
trations it can exert adverse effects, as illustrated by 
the intracerebroventricular injection of KYNA into 
rats, which results in decreased exploratory activity, 
stereotypy, ataxia, sleeping and respiratory depression 
(Vécsei & Beal, 1990). 
The process of neurodegeneration might be caused 
by glutamate or other endogenous excitotoxins, e.g. 
QUIN, which is a selective NMDA receptor agonist, 
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present in nanomolar concentrations in the brain. 
QUIN is one of the most important participants in the 
KP: it takes part in the final step of the KP leading to 
the synthesis of the essential co-enzyme nicotinamide 
adenine dinucleotide (NAD+) and NAD phosphate, 
which are essential for energy homeostasis and cel-
lular mechanisms (Rozsa et al., 2008; Robotka et al., 
2008). QUIN can exert pronounced effects on the 
NMDA-sensitive subpopulation of glutamate recep-
tors. It is present in nanomolar concentrations in the 
brain and is a weak, but specific competitive agonist 
of the NR2A and NR2B NMDA receptor subtypes. 
The increased QUIN level in astrocytes and neu-
rons can activate NMDA receptors, thereby induc-
ing excitotoxicity. It can provoke lipid peroxidation, 
potentiate oxidative stress (Sas et al., 2007) and in-
duce astrocytes to generate various cytokines, such 
as interferon-γ (IFN-γ), interleukin-1β and tumour 
necrosis factor-α (Braidy et al., 2009). It was thought 
that these inflammatory cytokines induce the activity 
of IDO, one of the first TRP metabolism enzymes. 
High expressions of QUIN and IDO have been ob-
served in the human hippocampus and neocortex 
(Guillemin et al., 2005a). IDO is induced in various 
types of inflammation, and activation of the immune 
system, the accumulation of QUIN and the up-regu-
lation of IDO are therefore considered to contribute 
to the pathophysiology of depression. 
Stone and colleagues demonstrated that free radi-
cals may contribute to the neurotoxic effects of QUIN 
(Stone et al., 2001). 3-OH-L-KYN generates reactive 
oxygen species and may therefore also cause neuro-
nal death (Sas et al., 2007), but this effect is NMDA 
receptor-independent.
The possible role of The Kynurenine 
paThway in The paThophysiology  
of depression
There appear to be no measured data on depressed 
patients as concerns the expression of enzymes re-
sponsible for the downstream metabolism of KYN 
(Hughes et al., 2012). The basis of the “neurodegenera-
tion hypothesis of depression” ascribed to Myint and 
Kim (2003) is an imbalance in the production of KP 
components in depression. As compared with healthy 
controls, depressed subjects were found to exhibit 
decreased KYNA concentration and an elevated TRP/
KYN ratio (Myint et al., 2007). Moreover, preclinical 
data indicated that KYN itself causes depressive be-
haviour in an animal model of depression (O’Connor 
et al., 2009). 
Schwarcz and colleagues reported that the KP is 
closely controlled by the immune system (Schwarcz 
et al., 2012). Dysregulation of this pathway, with 
changes in the levels of its metabolites resulting in 
the hyper- or hypofunction of active compounds, 
is associated with psychiatric diseases such as de-
pression and schizophrenia. With recently developed 
pharmacological agents, it is now possible to utilize 
novel therapeutic interventions and to achieve meta-
bolic equilibrium.
IFN-α has been applied as an immunotherapeutic 
agent, but a decreased serum level of TRP was ob-
served in patients who received this therapy, which 
was therefore associated with psychiatric side-effects 
such as depression (Bonaccorso et al., 2007). Coher-
ency has been described between changes in the pe-
ripheral blood levels of TRP, KYN and KYNA during 
IFN-α management (Raison et al., 2010). The plasma 
KYN/KYNA ratio is increased during IFN-α treat-
ment and this bears a relation to depressive symptoms 
(Wichers et al., 2005). 
In experimental animals, increased levels of pro-
inflammatory cytokines can induce behavioural 
changes (O’Connor et al., 2009). Raised levels of in-
flammatory cytokines have been observed in the brain 
and the periphery of depressive patients (Oxenkrug 
2010). The various factors that can activate IDO in 
the brain include oxidative stress, inflammation and 
infection (Heyes et al., 1993). Pro-inflammatory cy-
tokines activate IDO and kynurenine-3-monooxy-
genase, which converts KYN into 3-OH-KYN and 
shifts the KP towards the neurotoxic path. 
O’Connor and colleagues have recently reinforced 
the fact that IDO, as a critical molecular mediator, has 
a crucial role in the development of inflammation-in-
duced depressive-like behaviour. They demonstrated 
that the peripheral administration of lipopolysaccha-
ride (LPS) to mice activated IDO, which increased the 
brain 5-HT turnover and generated a depressive-like 
behavioural syndrome. According to the monoam-
ine hypothesis, the low levels of monoamine neuro-
transmitters in the brain e.g. 5-HT, dopamine and 
noradrenaline, can induce depression. The activation 
of IDO depresses the synthesis of 5-HT through the 
utilization of TRP which can contribute to the devel-
opment of depression. In contrast, the inhibition of 
IDO activation, either directly with an IDO antago-
nist, or indirectly with an anti-inflammatory drug 
that extenuates the LPS-induced expression of pro-
inflammatory cytokines, prevents the development of 
depressive-like behaviour. Interestingly, both an IDO 
antagonist and an anti-inflammatory drug are able to 
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restore the KYN/TRP ratio. Moreover, KYN admin-
istration to wild-type mice induced depressive-like 
behaviour dose-dependently (O’Connor et al., 2009).
ConneCTion beTween The Kynurenine 
paThway and CogniTive funCTions 
Structural changes caused by depression can be ob-
served in several brain regions, and especially in the 
hippocampus (Sheline, 2003). Several studies have 
suggested that KYNA can modulate hippocampus-
related cognitive functions and endogenously regulate 
the extracellular level of glutamate in the hippocam-
pus. An increased KYNA level can aggravate, whereas 
a reduced KYNA level can improve the cognitive 
functions (Pocivavsek et al., 2011). Increased KYNA 
concentrations, which cause excessive NMDA inhi-
bition and produce spatial working memory deficits, 
may deteriorate learning processes and reveal the 
influence of glia-derived molecules on cognitive func-
tions (Chess et al., 2007).
Neuroimaging studies in particular have demon-
strated a decreased hippocampal volume in patients 
with depression, who display severe impairments 
in selective attention, cognitive flexibility, executive 
function and working and verbal memory. There was 
no significant difference between depressed patients 
and healthy controls in the visual recall test. These 
results confirm observations of an intact short and 
long-term visual memory with an impaired executive 
function and attention in remission, findings sug-
gestive of an intact hippocampal function during 
remission (Sarosi, 2011).
Alterations in the kynurenine metabolism have 
been detected in the serum and also in post mortem 
studies of the brain in Alzheimer’s disease patients, 
and the changes in the kynurenine metabolite levels 
have proved to be associated with an impaired cog-
nitive function (Sas et al., 2007; Gulaj et al., 2010). 
It has also been observed that increased KP activation 
and changes in the levels of kynurenine metabolites 
correlate significantly with the cognitive performance 
in patients undergoing cardiac surgery (Forrest et al., 
2011). Alterations in the KP have been observed in 
other dementia disorders, e.g. Huntington’s disease 
and the AIDS dementia complex (Leblhuber et al., 
1998; Guillemin et al., 2005b). 
ConClusions
It has emerged that the KP is involved in the patho-
physiology of depression, variations in the concen-
trations of the KP metabolites contributing to the 
pathogenesis of this psychiatric disorder. Imbalances 
in the KP and TRP depletion are closely related with 
learning processes and may contribute to the develop-
ment of cognitive deficits. 
The involvement of KP imbalances in these patho-
physiological processes is evident and may be a prom-
ising target for the development of novel therapeutic 
strategies.
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A triptofán (TRP) szint változása, amelyet gyulladásos folyamat eredményeként a kinurenin 
útvonal aktiválódása okozhat, depresszió kialakulásához vezethet. A kinurenin útvonal, 
illetve a benne részt vevő metabolitok szintjének változásai valószínűsíthetően hozzájárulnak 
a depresszió patogeneziséhez. Az indolamin-2,3-dioxigenáz (IDO) az a kulcsmolekula, amely 
indukálja a TRP átalakulását kinureninné (KYN). Aktiválódását követően mind a neurotoxikus 
komponensek termelődése, mind pedig a csökkent perifériás TRP szint egyértelműen elő-
segíti a patofiziológiai folyamatokat. Összefoglalónk célja az, hogy áttekintést nyújtson 
a kinureninmetabolizmus depresszióban betöltött szerepéről, illetve a kognitív funkciókkal 
való kapcsolatáról.
Kulcsszavak: triptofán metabolizmus, kinurenin útvonal, kognitív deficit, depresszió     
A kinureninek és a kognitív funkció összefüggései,  
és lehetséges szerepük a depresszió kialakulásában
